Quantcast

Latest Rhinitis Stories

96dbb0ff1b77583d6160fb9d4d12f3bd1
2009-01-14 14:42:47

Following an investigation, federal health officials claim to have found no link between asthma drugs, such as Merck and Co. Inc.'s Singulair and an increased risk of suicide. The FDA announced on Tuesday that investigations are ongoing, but officials have discovered no link between the drugs and behavioral problems. "We have finished our analyses of all the data the companies submitted," said FDA spokeswoman Karen Riley. "But that doesn't mean we have closed the book on suicidality." In late...

2009-01-06 09:00:00

Lead candidate on track for IND submission first half of 2009. SAN DIEGO, Jan. 6 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced AM211, Amira's internally discovered oral drug candidate for the treatment and control of inflammatory and allergic diseases linked to the arachidonic acid pathway, is on target for submission of an IND to the U.S. Food and Drug Administration (FDA) by mid-2009 following the successful completion of Good Laboratory Practices (GLP) toxicity studies. AM211 is...

2008-12-16 07:00:00

HARBIN, China, Dec. 16 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), announced today that it successfully obtained the production approval from the State Food and Drug Administration (SFDA) in China for two additional drugs: Sodium Cromoglicate Eye Drops for the treatment of allergic...

2008-12-04 07:00:00

HARBIN, China, Dec. 4 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), announced today that its wholly-owned subsidiary, Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong"), obtained production approval from the State Food and Drug Administration ("SFDA") in China for a new nasal drop for the...

2008-11-10 18:00:05

Research findings presented at the 2008 American College of Allergy, Asthma and Immunology (ACAAI) Scientific Meeting revealed a significant cost savings associated with allergy immunotherapy (IT) in children with allergic rhinitis (AR). This pioneering study, supported by Greer, was summarized during an oral presentation by Cheryl Hankin, Ph.D., President and Chief Scientific Officer of BioMedEcon and principal investigator of the study, at the ACAAI meeting, held Nov. 6-11 in Seattle, Wash....

2008-11-07 09:00:05

Morria Biopharmaceuticals, a developer of anti-inflammatory drugs, has announced positive data from its ICH compliant Phase II equivalent multi-center study of MRX-4 in patients suffering from allergic rhinitis. MRX-4 was given as an intranasal spray formulation. The nasal allergen challenge study was conducted in allergic rhinitis patients outside of the local allergy season. MRX-4 was compared with both placebo (arm 1) and an intranasal steroid Rhinocort (as a positive control, arm 2)....

2008-11-06 11:17:34

LONDON and NEW YORK, Nov. 6 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, today announced positive data from its ICH compliant Phase II equivalent multi-center study of MRX-4 (n=105) in patients suffering from allergic rhinitis. MRX-4 was given as an intranasal spray formulation. The Nasal Allergen Challenge (NAC) study was conducted in allergic rhinitis patients outside of the local allergy season. MRX-4 was compared...

2008-11-05 09:00:34

WALTHAM, Mass., Nov. 5 /PRNewswire/ -- Decision Resources one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that physicians and patients respond to different marketing messages when considering which asthma medicine to use. Physicians indicate that brands conveying messages of improvements in patient-centered outcomes such as number of symptom-free days, reduction in acute exacerbations and quality of life receive more positive...

2008-10-30 12:00:21

Morria Biopharmaceuticals, a developer of novel, anti-inflammatory drugs, has announced the preliminary results from its recently completed Phase II equivalent study of MRX-4, in a nasal aerosol formulation, in 105 patients suffering from allergic rhinitis. The two-arm, randomized, multi-dose, double-blind, placebo-controlled study included Rhinocort as the steroid comparator arm. A secondary efficacy endpoint of this study was the effect of MRX-4 on inflammatory mediators or markers in the...

2008-10-29 12:00:07

LONDON, Oct. 29 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel, anti-inflammatory drugs, announced today the preliminary results from its recently completed Phase II equivalent study of MRX-4, in a nasal aerosol formulation, in 105 patients suffering from allergic rhinitis (AR). The two-arm, randomized, multi-dose, double-blind, placebo-controlled study included Rhinocort(R) as the steroid comparator arm. A secondary efficacy...


Word of the Day
cock-a-hoop
  • Exultant; jubilant; triumphant; on the high horse.
  • Tipsy; slightly intoxicated.
This word may come from the phrase 'to set cock on hoop,' or 'to drink festively.' Its origin otherwise is unclear. A theory, according to the Word Detective, is that it's a 'transliteration of the French phrase 'coq a huppe,' meaning a rooster displaying its crest ('huppe') in a pose of proud defiance.' Therefore, 'cock-a-hoop' would 'liken a drunken man to a boastful and aggressive rooster.'
Related